Known targets — ChEMBL curated mechanism
ABL1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB2AGTR1BCL2BCL2A1BCL2L1BCL2L10BCL2L2BCRBRAFCHRM1CHRNA10CHRNA9DRD1DRD2DRD3DRD4DRD5EGFRF2FLT1FLT4GCKGHSRGNRHRGRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BHTR1AHTR1BHTR1DHTR2AHTR2CHTR3AIDH2KDRKITMAOBMCL1MTTPPP4HBPDGFRBPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PIKFYVEROCK1ROCK2SLC18A2SLC6A2SLC6A3SLC6A4TACR1TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8gyrAgyrBparCparEpol
The experimentally established mechanism targets of Tirilazad. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR known ✓ | P00533 | 1/20 | 0.92 |
| ▸ | ADRB2 known ✓ | P07550 | 1/20 | 0.92 |
| ▸ | ADRA2A known ✓ | P08913 | 1/20 | 0.92 |
| ▸ | ADRA2C known ✓ | P18825 | 1/20 | 0.92 |
| ▸ | DRD1 known ✓ | P21728 | 1/20 | 0.92 |
| ▸ | HTR2A known ✓ | P28223 | 1/20 | 0.92 |
| ▸ | HTR2C known ✓ | P28335 | 1/20 | 0.92 |
| ▸ | DRD3 known ✓ | P35462 | 1/20 | 0.92 |
| ▸ | CHRM1 known ✓ | P11229 | 1/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.92 |
| ▸ | PGR | P06401 | 2/20 | 0.92 |
| ▸ | AR | P10275 | 2/20 | 0.92 |
| ▸ | LCK | P06239 | 1/20 | 0.92 |
| ▸ | FYN | P06241 | 1/20 | 0.92 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.92 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.92 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.92 |
| ▸ | HRH2 | P25021 | 1/20 | 0.92 |
| ▸ | MAPK3 | P27361 | 1/20 | 0.92 |
| ▸ | PDE4A | P27815 | 1/20 | 0.92 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tirilazad SCHEMBL15263492 | 1.00 | KCNH2 (0.92) | KCNH2PGRAREGFRLCK | |
| Tirilazad SCHEMBL10695568 | 0.99 | KCNH2 (0.93) | KCNH2PGRAREGFRLCK | |
| Tirilazad SCHEMBL29373864 | 0.99 | KCNH2 (0.93) | KCNH2PGRAREGFRLCK | |
| Tirilazad SCHEMBL9069954 | 0.99 | KCNH2 (0.93) | KCNH2PGRAREGFRLCK | |
| Tirilazad SCHEMBL9221827 | 0.99 | KCNH2 (0.93) | KCNH2PGRAREGFRLCK | |
| Tirilazad SCHEMBL9724980 | 0.99 | KCNH2 (0.93) | KCNH2PGRAREGFRLCK | |
| Tirilazad SCHEMBL10697047 | 0.99 | KCNH2 (0.93) | KCNH2PGRAREGFRLCK | |
| Tirilazad SCHEMBL1650168 | 0.99 | KCNH2 (0.93) | KCNH2PGRAREGFRLCK | |
| Tirilazad SCHEMBL483318 | 0.96 | PGR (1.00) | KCNH2PGRAREGFRLCK | |
| Tirilazad SCHEMBL4938280 | 0.96 | PGR (1.00) | KCNH2PGRAREGFRLCK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 985 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3274008-B1 | DETECTION OF BRAIN INJURY | THE UNIV OF MONTANA (US) | 2024-12-04 | — | — | EP | claimed |
| EP-3875078-A1 | COMPOUNDS FOR THE TREATMENT OF COVID-19 | Dompe' Farmaceutici S.P.A. (IT) | 2021-09-08 | — | — | EP | claimed |
| US-10202649-B2 | Detection of traumatic brain injury | THE UNIVERSITY OF MONTANA (US) | 2019-02-12 | — | — | US | claimed |
| EP-3274008-A1 | DETECTION OF BRAIN INJURY | The University of Montana (US) | 2018-01-31 | — | — | EP | claimed |
| CN-107427614-A | The detection of brain damage | 蒙大拿大学 | 2017-12-01 | — | — | CN | claimed |
| US-20170268058-A1 | Detection of Traumatic Brain Injury | GLIA DIAGNOSTICS PTY LTD (AU) | 2017-09-21 | — | — | US | claimed |
| CN-104288168-B | Purposes of the cryptogenin in the medicine for preparing the disease for being used for treating and/or prevent microglia to mediate | 吉林敖东洮南药业股份有限公司 | 2017-08-18 | — | — | CN | claimed |
| US-9605315-B2 | Detection of traumatic brain injury | THE UNIVERSITY OF MONTANA (US) | 2017-03-28 | — | — | US | claimed |
| WO-2016153549-A1 | DETECTION OF BRAIN INJURY | THE UNIVERSITY OF MONTANA (US) | 2016-09-29 | — | — | WO | claimed |
| US-20150344954-A1 | Detection of Brain Injury | GLIA DIAGNOSTICS PTY LTD (AU) | 2015-12-03 | — | — | US | claimed |
| EP-0759750-A4 | COMPOSITIONS FOR TREATMENT OF CHRONIC INFLAMMATORY DISEASES | SHAPIRO HOWARD K (US) | 1998-05-27 | — | — | EP | claimed |
| EP-0784471-A4 | MULTI-FACETED METHOD TO REPRESS REPRODUCTION OF LATENT VIRUSES IN HUMANS AND ANIMALS | DYKE KNOX VAN (US) | 1997-11-19 | — | — | EP | claimed |
| CN-1156962-A | Co-soluble parenteral formulation of tirilade | UPJOHN CO (US) | 1997-08-13 | — | — | CN | claimed |
| EP-0784471-A2 | MULTI-FACETED METHOD TO REPRESS REPRODUCTION OF LATENT VIRUSES IN HUMANS AND ANIMALS | Van Dyke, Knox (US) | 1997-07-23 | — | — | EP | claimed |
| EP-0778775-A1 | COSOLVENT PARENTERAL FORMULATION OF TIRILAZAD | PHARMACIA & UPJOHN COMPANY (US) | 1997-06-18 | — | — | EP | claimed |
| WO-1997016967-A1 | COMPOSITIONS AND METHODS FOR PROMOTING BLOOD COMPONENT SURVIVAL | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. (US) | 1997-05-15 | — | — | WO | claimed |
| EP-0759750-A1 | COMPOSITIONS FOR TREATMENT OF CHRONIC INFLAMMATORY DISEASES | SHAPIRO, Howard, K. (US) | 1997-03-05 | — | — | EP | claimed |
| WO-1996010402-A1 | MULTI-FACETED METHOD TO REPRESS REPRODUCTION OF LATENT VIRUSES IN HUMANS AND ANIMALS | DYKE KNOX VAN (US) | 1996-04-11 | — | — | WO | claimed |
| WO-1996006618-A1 | COSOLVENT PARENTERAL FORMULATION OF TIRILAZAD | PHARMACIA & UPJOHN COMPANY (US) | 1996-03-07 | — | — | WO | claimed |
| WO-1995031194-A1 | COMPOSITIONS FOR TREATMENT OF CHRONIC INFLAMMATORY DISEASES | SHAPIRO HOWARD K (US) | 1995-11-23 | — | — | WO | claimed |